Ignite Creation Date:
2025-12-24 @ 4:39 PM
Ignite Modification Date:
2026-01-03 @ 6:49 AM
Study NCT ID:
NCT05493566
Status:
RECRUITING
Last Update Posted:
2025-04-01
First Post:
2022-08-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Sponsor:
Emory University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-11-01
Start Date Type:
ACTUAL
Primary Completion Date:
2026-01-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-01-07
Completion Date Type:
ESTIMATED
First Submit Date:
2022-08-02
First Submit QC Date:
None
Study First Post Date:
2022-08-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-26
Last Update Post Date:
2025-04-01
Last Update Post Date Type:
ACTUAL